Clinical Trials · NCT02324998
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Enrollment
- 20
- Start date
- Dec 2016
- Locations
- 1 site, United Kingdom
- Primary endpoint
- Determination of PARP Inhibition